Needham Raises Price Target on AtriCure to $70 From $64, Keeps Buy Rating
Needham has maintained its 'Buy' rating on AtriCure, Inc. while increasing its price target for the company's shares from $64 to $70.
Filings · News reference
AtriCure Insider Stock Sale
An insider at AtriCure sold shares valued at approximately $546,260, according to a recent SEC filing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Raises AtriCure Price Target to $70
BTIG maintained a Buy rating on AtriCure and increased its price target from $63 to $70.
AtriCure Reports Third-Quarter 2026 Financial Results
AtriCure announced its Q3 2026 financial results, reporting $154.5 million in revenue and $4.1 million in net income.
Citizens Raises Price Target on AtriCure to $68.00
Citizens has increased its price target for AtriCure, Inc. from $52.00 to $68.00 while maintaining a Market Outperform rating.
Citizens Maintains Market Outperform on AtriCure, Raises Price Target to $68
BTIG Maintains Buy on AtriCure, Raises Price Target to $63
BTIG analyst Ryan Zimmerman maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $55 to $63.